pd-l1 inhibitor incb086550
pd-l1 inhibitor incb086550: 4 clinical trials tracked.
pd-l1 inhibitor incb086550 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about pd-l1 inhibitor incb086550, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (4)
An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550
Primary endpoint: Total recovery of radioactivity from urine and feces.
A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors
Primary endpoint: Objective Response Rate (ORR)
A Phase 1 Study Exploring the Safety, Tolerability, and Pharmacokinetics of INCB086550 in Japanese Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAE)
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Primary endpoint: Number of treatment-emergent adverse events